Treatment with ambroxol a medication used to treat respiratory conditions associated with excessive mucus reversed bone damage and decreased the excessive liver and spleen volume of a 5-year-old girl with Gaucher disease (GD) type 1, a case study shows.
Titled Ambroxol improves skeletal and hematological manifestations on a child with Gaucher disease, the case study was published in the Journal of Human Genetics.
Mutations in the GBA gene in people with Gaucher alter the formation of the beta-glucocerebrosidase enzyme, which in turn leads to the toxic buildup of a lipid (fat) called glucocerebroside in the spleen, liver, lung, bone, and brain cells.
Ambroxol, an available cough and cold medicine, is known to boost beta-glucocerebrosidase activity. It works as a chaperone therapy, a type of small molecule that binds to faulty enzymes and helps them fold properly. High-dose oral ambroxol also has shown promise in easing the neurological symptoms of patients with GD type 3.
Enzyme replacement therapy (ERT) has been the mainstay treatment for people with GD type 1. It has led to significant improvements in complications such as the abnormal enlargement of abdominal organs, called hepatosplenomegaly, and blood disorders. However, it has shown limited efficacy to the progressive skeletal manifestations in GD, the researchers said.
A team from China now described the case of a 5-year-old girl with complaints of severe pain in both legs, which restrained her from walking independently. According to her parents, the child had intermittent GD-related bone crises over two years. These were worse in the winter and eased upon several days of rest.
Clinical examination revealed enlargement of the girls spleen and liver. Imaging showed that both femurs, or thighbones, had aseptic necrosis, meaning that the bone tissue had died due to lack of blood supply. Aseptic necrosis is a well-known skeletal complication in GD.
Results of abone marrow biopsy and a measurement of beta-glucocerebrosidase activity levels were consistent with a diagnosis of GD. Genetic testing showed the girl had two distinct mutations in the GBA gene.
Given her age and manifestations, ERT and substrate reduction therapy were both contraindicated. After obtaining parental consent, doctors enrolled the patient in a compassionate use clinical protocol for ambroxol.
The girl received up to 15 mg/kg of daily ambroxol for three years without any side effects. No further bone crisis was seen after treatment initiation. Importantly, ambroxol reduced liver and spleen volume, and slightly increased white and red blood cell counts after two years.
In addition, disease severity gradually decreased after almost three years, as measured by the blood activity of chitotriosidase, a GD biomarker.
Annual imaging also showed a reversal of damage in the top part of the girls femurs, allowing the near-normal growth of the femoral heads.
Cellular assays revealed increased activity of beta-glucocerebrosidase in the patients lymphocytes, a type of white blood cell. The scientists suggested that ambroxols small size might contribute to its efficient penetration into bone tissue as indicated by the observed skeletal improvements.
In conclusion, this is the first report describing the therapeutic effects of oral ABX [ambroxol] on the bone and hematological manifestations of a child with an established [GD1], the scientists said.
Randomized and controlled clinical trials are necessary to further assess and confirm these findings, they added.
With over three years of experience in the medical communications business, Catarina holds a BSc. in Biomedical Sciences and a MSc. in Neurosciences. Apart from writing, she has been involved in patient-oriented translational and clinical research.
Total Posts: 24
Jos is a science news writer with a PhD in Neuroscience from Universidade of Porto, in Portugal. He has also studied Biochemistry at Universidade do Porto and was a postdoctoral associate at Weill Cornell Medicine, in New York, and at The University of Western Ontario in London, Ontario, Canada. His work has ranged from the association of central cardiovascular and pain control to the neurobiological basis of hypertension, and the molecular pathways driving Alzheimers disease.
See the rest here:
- human genetics | Description, Chromosomes, & Inheritance ... - May 19th, 2020
- Human genetics - Wikipedia - May 19th, 2020
- COVID-19 Pandemic: Global Risks of More Complex Character and the Visions of the Future World - Valdai Discussion Club - May 19th, 2020
- Rothamsted turn to harvesting coronavirus data - Lab News - May 19th, 2020
- Complement genes add to sex-based vulnerability in lupus and schizophrenia - UAB News - May 19th, 2020
- DU to set up School of Public Health - The Indian Express - May 19th, 2020
- Covid-19 research: 45 Bengaluru startups working on medicine, testing methods and vaccine - Economic Times - May 19th, 2020
- Immortalized Cell Line Market Development, Trends, Key Driven Factors, Segmentation And Forecast to 2020-2026 - Cole of Duty - May 19th, 2020
- Worlds Shortest Population Reveal the Largest Genetic Contributor to Height - Technology Networks - May 15th, 2020
- Group of Genes Have Altered Expression in Autism - Technology Networks - May 15th, 2020
- Why can two young and healthy individuals be affected so differently by coronavirus? - Health24 - May 15th, 2020
- Amgen To Present At The Bank Of America Merrill Lynch Virtual Global Healthcare Conference - BioSpace - May 15th, 2020
- Viewpoint: Darwin's 'Descent of Man' is both deeply disturbing and more relevant than ever - Genetic Literacy Project - May 15th, 2020
- Study Finds Low Proportion of Individuals With Autism Receive Recommended Genetic Tests - Technology Networks - May 15th, 2020
- Cats can catch Covid-19 from other cats. The question is: Can we? - STAT - May 15th, 2020
- Deficient Expression of DGCR8 in Human Testis is Related to Spermatoge | IJGM - Dove Medical Press - May 15th, 2020
- Prevail Therapeutics Reports First Quarter 2020 Financial Results and Business Highlights - GlobeNewswire - May 15th, 2020
- Fulcrum Therapeutics, Inc. (FULC) Q1 2020 Earnings Call Transcript - The Motley Fool - May 15th, 2020
- Scientists concerned that coronavirus is adapting to humans - The Guardian - May 11th, 2020
- Coronavirus quickly spread around the world starting late last year, new genetic analysis shows - CNN - May 11th, 2020
- Your genes could determine whether the coronavirus puts you in the hospital and we're starting to unravel which ones matter - The Conversation US - May 11th, 2020
- Yes, COVID-19 is mutating, here's what you need to know - ABC News - May 11th, 2020
- Conservatives Are Not the Only Ones Who Ignore Facts and the Science - Merion West - May 11th, 2020
- Coronavirus in Scotland: Charity warns Covid will cause a spike in ME cases - as it calls for 'harmful' exercise treatment to be banned -... - May 11th, 2020
- Dr. Misaki Wayengera: The Man Behind Uganda's Covid 19 Test Kits - New Vision - May 11th, 2020
- Its In The Genes? Scientists Think Coronavirus Exploits Silent Hidden Mutations In The Body - International Business Times - May 11th, 2020
- From blood clots to 'Covid toe': Experts confounded by series of medical mysteries - The Straits Times - May 11th, 2020
- MET 2020 Slot booking to commence on July 15, Examination dates available at manipal.edu - Jagran Josh - May 11th, 2020
- Vitagene Launches The First FDA Authorized Saliva based Zero Contact COVID-19 At Home Test - Business Wire - May 10th, 2020
- Genetics in focus after coronavirus deaths of siblings and twins - The Guardian - May 10th, 2020
- 'An anvil on my chest': What it's like to have COVID-19 - LancasterOnline - May 10th, 2020
- Coronavirus may have spread to humans as early as October 2019 - study - The Jerusalem Post - May 10th, 2020
- Team reveals genomic history of ancient civilizations in the Andes - UC Santa Cruz - May 10th, 2020
- Regeneron Reports First Quarter 2020 Financial and Operating Results - BioSpace - May 10th, 2020
- Scientists at Ben-Gurion University of the Negev Develop Anti-Coronavirus Surface Coating Based on Nanomate... - The Auto Channel - May 10th, 2020
- COVID-19 and food security - Fitzwilliam College, University of Cambridge - May 10th, 2020
- Val Sheffield elected to the American Academy of Arts and Sciences - Iowa Now - May 1st, 2020
- DNA gives clues into risk of developing Alzheimer's disease and other dementias - Alabama NewsCenter - May 1st, 2020
- Rare Gene Discovered That Nearly Doubles Risk of Developing a Neurodegenerative Disease - Clinical OMICs News - May 1st, 2020
- Progress in understanding the genetic basis of mental health - SFARI News - May 1st, 2020
- Coronavirus was widespread in UK at very start of pandemic, says genetics expert - Sky News - May 1st, 2020
- This is how you do the genetics heritage filter on Instagram that everyone's doing - The Tab - May 1st, 2020
- COVID-19 vaccine in Ireland could take a year and a half - IrishCentral - May 1st, 2020
- MRC scientists elected Fellows of the Royal Society - Cambridge Network - May 1st, 2020
- Parkinson's discovery implicates "second brain" in the gut - New Atlas - May 1st, 2020
- Humans: are we the most effective vector of disease? - BugBitten - BMC Blogs Network - May 1st, 2020
- Could genetics explain why some COVID-19 patients fare worse than others? - Live Science - April 27th, 2020
- Human Genetics Market Overview, Top Companies, Region, Application and Global Forecast by 2026 - Latest Herald - April 27th, 2020
- American Academy of Arts & Sciences Elects UVM's Wallace to Its Membership - UVM News - April 27th, 2020
- The PBS documentary The Gene showcases genetics promise and pitfalls - Science News - April 9th, 2020
- Few clinical trials are done in Africa: COVID-19 shows why this urgently needs to change - The Conversation Africa - April 9th, 2020
- UCLA web app will enlist publics help in slowing the spread of COVID-19 - Newswise - April 9th, 2020
- Why does the new coronavirus kill some people and barely affect others? - Wilkes-Barre Citizens Voice - April 9th, 2020
- COVID-19: Few Clinical Trials are Done in Africa. This Needs to Change ASAP. - The Wire - April 9th, 2020
- 'Behavioral suppression' needed to decrease coronavirus infections in Japan: experts - The Mainichi - April 9th, 2020
- The secret call of the wild: how animals teach each other to survive - The Guardian - April 9th, 2020
- Yann Joly on the fight against genetic discrimination - McGill Reporter - April 2nd, 2020
- Science to the rescue? How modern genetics could help save the world from coronavirus - Genetic Literacy Project - April 2nd, 2020
- Oldest human genetic data gleaned from 1.8-million-year-old tooth Haaretz - News Collective - April 2nd, 2020
- Science to the rescue? How modern genetics could help save the world from coronavirus - Alliance for Science - Alliance for Science - April 2nd, 2020
- BHU department claims to have discovered new technology to test COVID-19 - Jagran Josh - April 2nd, 2020
- Stealth BioTherapeutics Reports Fiscal Year 2019 Financial Results And Recent Business Highlights - BioSpace - April 2nd, 2020
- Researchers at U of T developing antibodies to 'neutralize' novel coronavirus before it invades cells - News@UofT - April 2nd, 2020
- What is coronavirus and Covid-19? An explainer - KTVZ - April 2nd, 2020
- Plasmid Market was Valued at US$ 89.52 million in 2018 and is Estimated to Reach US$ 447.68 Million by 2027, growing at a CAGR of 19.5% over the... - April 2nd, 2020
- The genetic architecture of the human cerebral cortex - Science Magazine - March 26th, 2020
- The Coronavirus Pandemic Shows Us The Importance Of Combatting Climate Change - Forbes - March 26th, 2020
- Kallyope Inc. Announces $112M Series C Financing to Support First Clinical Trials and Advance Portfolio of Programs Targeting the Gut-Brain Axis - P&T... - March 26th, 2020
- IN CONSERVATION: DR. JEFF STROVEL, CEO of VERALOX THERAPEUTICS - BioBuzz - March 26th, 2020
- How healthtech startup Bione aims to use genetic testing in the fight against coronavirus - YourStory - March 26th, 2020
- Coronavirus: Massive gap in US response revealed after scientists learn colleague tested positive through twee - MEAWW - March 26th, 2020
- Avera announces ability to test for COVID-19 in South Dakota - The Dickinson Press - March 24th, 2020
- University of Utah experts advise caution over drugs hyped as possible coronavirus treatments - Salt Lake Tribune - March 24th, 2020
- Invitae and Muscular Dystrophy Association (MDA) Expand Access to No-Charge Genetic Testing in the US and Canada - PRNewswire - March 24th, 2020
- Studying the African genome could yield new medical treatments for everyone - Genetic Literacy Project - March 24th, 2020
- Human Genetics Market Higher Growth Rate / CAGR over the Forecast Period to 2026 by Key Players like QIAGEN, Agilent Technologies, Illumina - New Day... - March 16th, 2020
- Coronavirus is hard on older people and scientists aren't sure why - NBCNews.com - March 16th, 2020
- Researchers study irregular horse heartbeats, hoping to find a cure - Minnesota Daily - March 16th, 2020
- Dr. John T. Macdonald Foundation seeking to fund community-based organizations with major grant dollars - Miami's Community Newspapers - March 16th, 2020
- A book that could save lives: Adam Rutherford's How to Argue with a Racist reviewed - Spectator.co.uk - March 16th, 2020